Sunrise Group’s Dreem Health, a virtual sleep clinic for the treatment and evaluation of conditions such as sleep apnoea, has become the first sleep care service to join Amazon’s Health Benefits Connector.
Acting as a bridge between customers and virtual-care providers, Amazon’s connector is part of the e-commerce giant’s broader healthcare ecosystem and is intended to help US customers discover and make use of health benefits that are potentially already available through their employer or insurer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Dreem Health is positioned to improve patient access to sleep diagnostics and therapy from home, removing geographic, logistical, and financial barriers, Sunrise Group stated.
“By connecting customers with services like Dreem Health through Health Benefits Connector, we’re helping make it easier to discover care that supports better health outcomes,” explained John Singerling, head of strategic growth and network development for Amazon Health Services.
Dreem Clinic via Amazon provides users with a means to access sleep services and the company’s lead product, Dreem 3S, an electroencephalogram (EEG) headband that is used to diagnose sleep conditions, including insomnia and sleep apnoea.
Cleared by the US Food and Drug Administration (FDA) in August 2023, Dreem 3S provides diagnostics without requiring clinic visits, while Dreem’s virtual clinic offers patient support to ensure treatment adherence.
Laurent Martinot, CEO of Sunrise Group, commented: “By joining Amazon’s Health Benefits Connector, we’re helping surface sleep care as a covered benefit and making it easier for people to take the first step toward better sleep.”
According to GlobalData analysis, the patient monitoring market, of which EEG data collection is a part, is growing at a CAGR of 1.8% and is forecast to reach a valuation of around $25.9bn in 2035, up from around $21.4bn in 2025.
Alongside companies such as Beacon Biosignals, which also offer an EEG headband for diagnosing sleep issues, these technologies are also being used to bring precision neuroscience to clinical trials.
In November 2025, Beacon, which recently closed a $97m financing round, expanded a partnership with Takeda that centred on at-home sleep monitoring for trials related to sleep disorders. Under the expanded partnership, the companies are using Beacon’s technology to expedite sleep biomarkers and pattern development with the aim of supporting new diagnostic approaches and closing care gaps for individuals with narcolepsy.
